Invivyd, Inc. (NASDAQ: IVVD) announced that enrollment in its Phase 3 LIBERTY clinical trial is complete, with topline data expected ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE